However, new clinical studies will need to be performed to test the clinical feasibility of using GSVA for preventative and personalized medicine approaches as seen previously in studies on glioma [72], subtypes of liver cancer [73] and for response to dual CXCR2/CCR5 therapy [69]. This evidence concerns the gene CXCR2 and glioma.